BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 18412020)

  • 21. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
    Fraccarollo D; Galuppo P; Motschenbacher S; Ruetten H; Schäfer A; Bauersachs J
    Basic Res Cardiol; 2014 Jul; 109(4):421. PubMed ID: 24907870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis.
    Peters H; Wang Y; Loof T; Martini S; Kron S; Krämer S; Neumayer HH
    Kidney Int; 2004 Dec; 66(6):2224-36. PubMed ID: 15569311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase, on human NADPH oxidase system from THP-1 cells.
    Borges de Oliveira-Junior E; Thomazzi SM; Rehder J; Antunes E; Condino-Neto A
    Eur J Pharmacol; 2007 Jul; 567(1-2):43-9. PubMed ID: 17499238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle.
    Báu FR; Mónica FZ; Priviero FB; Baldissera L; de Nucci G; Antunes E
    Eur J Pharmacol; 2010 Jul; 637(1-3):171-7. PubMed ID: 20399768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct sGC activation bypasses NO scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction.
    Raat NJ; Tabima DM; Specht PA; Tejero J; Champion HC; Kim-Shapiro DB; Baust J; Mik EG; Hildesheim M; Stasch JP; Becker EM; Truebel H; Gladwin MT
    Antioxid Redox Signal; 2013 Dec; 19(18):2232-43. PubMed ID: 23697678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged therapy with the soluble guanylyl cyclase activator BAY 60-2770 restores the erectile function in obese mice.
    Silva FH; Leiria LO; Alexandre EC; Davel AP; Mónica FZ; De Nucci G; Antunes E
    J Sex Med; 2014 Nov; 11(11):2661-70. PubMed ID: 25196910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nitric oxide and heat shock protein 90 activate soluble guanylate cyclase by driving rapid change in its subunit interactions and heme content.
    Ghosh A; Stasch JP; Papapetropoulos A; Stuehr DJ
    J Biol Chem; 2014 May; 289(22):15259-71. PubMed ID: 24733395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice.
    Leiria LO; Silva FH; Davel AP; Alexandre EC; Calixto MC; De Nucci G; Mónica FZ; Antunes E
    J Urol; 2014 Feb; 191(2):539-47. PubMed ID: 24050894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells.
    El-Sehemy A; Chang AC; Azad AK; Gupta N; Xu Z; Steed H; Karsan A; Fu Y
    Cell Signal; 2013 Dec; 25(12):2780-7. PubMed ID: 24041655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Receptor-controlled phosphorylation of alpha 1 soluble guanylyl cyclase enhances nitric oxide-dependent cyclic guanosine 5'-monophosphate production in pituitary cells.
    Kostic TS; Andric SA; Stojilkovic SS
    Mol Endocrinol; 2004 Feb; 18(2):458-70. PubMed ID: 14630997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble Guanylate Cyclase Modulators, BAY 41-2272 and BAY 60-2770, Inhibit Human and Rabbit Prostate Contractility.
    Calmasini FB; Alexandre EC; Silva FH; De Nucci G; Antunes E; D'Ancona CA; Mónica FZ
    Urology; 2016 Aug; 94():312.e9-312.e15. PubMed ID: 27131967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.
    Füllhase C; Hennenberg M; Sandner P; Strittmatter F; Niedworok C; Bauer RM; Gratzke C; Soler R; Stief C; Andersson KE
    Neurourol Urodyn; 2015 Nov; 34(8):787-93. PubMed ID: 25230878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidative stress impairs vasorelaxation induced by the soluble guanylyl cyclase activator BAY 41-2272 in spontaneously hypertensive rats.
    Priviero FB; Zemse SM; Teixeira CE; Webb RC
    Am J Hypertens; 2009 May; 22(5):493-9. PubMed ID: 19247264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble guanylate cyclase modulators blunt hyperoxia effects on calcium responses of developing human airway smooth muscle.
    Britt RD; Thompson MA; Kuipers I; Stewart A; Vogel ER; Thu J; Martin RJ; Pabelick CM; Prakash YS
    Am J Physiol Lung Cell Mol Physiol; 2015 Sep; 309(6):L537-42. PubMed ID: 26254425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tetrahydrobiopterin protects soluble guanylate cyclase against oxidative inactivation.
    Schmidt K; Neubauer A; Kolesnik B; Stasch JP; Werner ER; Gorren AC; Mayer B
    Mol Pharmacol; 2012 Sep; 82(3):420-7. PubMed ID: 22648973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BAY 60-2770 activates two isoforms of nitric oxide sensitive guanylyl cyclase: Evidence for stable insertion of activator drugs.
    Sömmer A; Sandner P; Behrends S
    Biochem Pharmacol; 2018 Jan; 147():10-20. PubMed ID: 29155144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heme oxygenase-1 deficiency leads to alteration of soluble guanylate cyclase redox regulation.
    Jones AW; Durante W; Korthuis RJ
    J Pharmacol Exp Ther; 2010 Oct; 335(1):85-91. PubMed ID: 20605906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels.
    Stasch JP; Schmidt PM; Nedvetsky PI; Nedvetskaya TY; H S AK; Meurer S; Deile M; Taye A; Knorr A; Lapp H; Müller H; Turgay Y; Rothkegel C; Tersteegen A; Kemp-Harper B; Müller-Esterl W; Schmidt HH
    J Clin Invest; 2006 Sep; 116(9):2552-61. PubMed ID: 16955146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGC.
    Elgert C; Rühle A; Sandner P; Behrends S
    Biochem Pharmacol; 2019 May; 163():142-153. PubMed ID: 30753814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra.
    Toque HA; Antunes E; Teixeira CE; De Nucci G
    Urology; 2008 Sep; 72(3):711-5. PubMed ID: 18359064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.